Clinical Approach to Acne (Hormonal Pattern)

Comprehensive Practical Framework

1
Symptom Overview
Overview
2
Pathophysiology
Mechanism
3
History Taking
History
4
Physical Examination
Examination
5
Differential Diagnosis
Differential
6
Investigations
Workup
7
Clinical Decision-Making
Algorithm
8
Pearls and Pitfalls
Summary

1. Symptom Overview

Understanding the clinical significance and classification of hormonal acne

Acne vulgaris affects approximately 85% of adolescents and young adults, but hormonal acne specifically persists or develops in 12-22% of adult women. Adult female acne accounts for up to 50% of dermatology visits for acne, with the majority demonstrating a hormonal pattern. In gynecology practice, hormonal acne is a common presenting complaint in women with polycystic ovary syndrome (PCOS), occurring in 20-40% of affected patients. The psychological burden is significant, with studies showing that adult women with acne have higher rates of anxiety and depression compared to age-matched controls.

Definition

Hormonal acne refers to acne vulgaris that is predominantly driven by androgen excess or end-organ hypersensitivity to androgens. It is characterized by inflammatory lesions concentrated along the lower face, jawline, and neck, with flares that correlate with menstrual cycle phases. Unlike adolescent acne, hormonal acne in adult women often persists beyond the teenage years or presents de novo after age 25, and responds suboptimally to conventional topical therapies alone.

Key Epidemiology

Prevalence: Adult female acne affects 12-22% of women aged 25-44
PCOS association: 20-40% of women with PCOS have acne as a presenting feature
Persistence: 50% of women with teenage acne continue to have acne in their 20s
Late-onset: Approximately 25% of adult female acne begins after age 25
Premenstrual flares: 60-70% of women report acne worsening in the week before menses

Classification by Duration and Onset

Category	Description	Common Causes	Clinical Significance
Persistent Acne	Acne continuing from adolescence into adulthood without remission	Genetic predisposition, underlying hormonal dysfunction, inadequate prior treatment	Most common pattern; warrants hormonal evaluation if severe or resistant
Late-Onset Acne	New-onset acne after age 25 with no significant adolescent history	PCOS, hormonal changes, medication-induced, new hormonal contraception	Higher likelihood of underlying endocrine disorder; requires thorough workup
Recurrent Acne	Acne that cleared after adolescence but returned in adulthood	Hormonal shifts (pregnancy, postpartum, perimenopause), discontinuation of oral contraceptives	Often correlates with identifiable hormonal triggers; good response to hormonal therapy
Cyclical Flares	Periodic worsening tied to menstrual cycle phases	Premenstrual progesterone and androgen fluctuations	Suggestive of hormonal etiology even with normal androgen levels

Classification by Morphology

Non-Inflammatory Lesions

Open comedones (blackheads): Dilated follicles with oxidized keratin plugs; less common in hormonal acne pattern.

Closed comedones (whiteheads): Obstructed follicles beneath intact epidermis; may be present but not predominant in hormonal acne.

Inflammatory Lesions

Papules: Small, raised, erythematous lesions less than 5 mm; common in hormonal acne.

Pustules: Papules with visible purulent material; typical of hormonal pattern.

Nodules and cysts: Deep, painful lesions greater than 5 mm; indicate severe hormonal acne with higher scarring risk.

Classification by Distribution Pattern

Pattern	Distribution	Suggests
U-Zone (Hormonal)	Lower face, jawline, chin, anterior neck	Androgen-driven acne; higher density of androgen-sensitive sebaceous glands in this region
T-Zone (Classic)	Forehead, nose, central chin	More typical of adolescent acne; seborrheic distribution
Perioral	Around mouth, nasolabial folds	May indicate perioral dermatitis (mimicker); consider topical steroid use
Truncal	Chest, upper back, shoulders	When combined with facial acne, suggests significant androgen excess
Diffuse	Widespread face, neck, and trunk involvement	Severe hormonal dysfunction; consider PCOS, congenital adrenal hyperplasia, androgen-secreting tumors

Classification by Timing and Triggers

Timing Pattern	Description	Mechanism
Premenstrual Flares	Worsening 7-10 days before menses, improving after menstruation	Rising progesterone has mild androgenic activity; relative estrogen decline reduces anti-androgenic effect
Periovulatory	Flares around mid-cycle (days 12-16)	Luteinizing hormone surge stimulates theca cell androgen production
Post-Contraceptive	Onset or worsening after stopping hormonal contraception	Rebound androgen effect after suppression; may unmask underlying PCOS
Pregnancy-Related	New onset or worsening during pregnancy, especially first trimester	Increased sebaceous gland activity from hormonal changes; limited treatment options
Perimenopausal	New or worsening acne in the menopausal transition (ages 45-55)	Declining estrogen with relative androgen excess; unopposed adrenal androgens

Classification by Severity

Grade	Clinical Features	Lesion Types	Management Implications
Mild	Few scattered lesions, minimal inflammation	Predominantly comedones, few papules	May respond to topical therapy; hormonal therapy optional
Moderate	Multiple inflammatory lesions, more widespread distribution	Papules, pustules, some comedones	Combination therapy recommended; hormonal treatment often beneficial
Severe	Numerous inflammatory lesions, nodules, or cysts present	Nodules, cysts, extensive papulopustular disease	Hormonal therapy indicated; consider isotretinoin referral; high scarring risk

Key Concept: The Hormonal Acne Triad

In gynecology practice, always consider the “Hormonal Acne Triad” when evaluating adult women with acne:

Distribution: Predominant involvement of the lower face, jawline, and chin (U-zone)
Timing: Cyclical flares correlating with menstrual cycle, particularly premenstrual worsening
Associated features: Presence of other signs of androgen excess (hirsutism, irregular menses, androgenic alopecia)

The presence of two or more features strongly suggests hormonal etiology and warrants endocrine evaluation, even if individual androgen levels are within normal range.

Impact on Quality of Life

Psychosocial Burden — Do Not Underestimate

Hormonal acne in adult women carries significant psychological impact that may be disproportionate to clinical severity:

Depression and anxiety: 2-3 times higher rates compared to women without acne
Social withdrawal: Avoidance of social situations, workplace impairment
Body dysmorphic features: Excessive focus on perceived skin flaws
Impact on relationships: Intimacy avoidance, reduced self-esteem
Financial burden: Expenditure on skincare products, cosmetics, and treatments

Always assess psychosocial impact regardless of clinical severity, and consider earlier intervention in patients with significant distress.

2. Pathophysiology and Mechanisms

Understanding the underlying mechanisms of hormonal acne

Acne is a multifactorial disease of the pilosebaceous unit, but in hormonal acne, androgens play the central pathogenic role. Understanding the interplay between hormonal signaling, sebaceous gland function, follicular keratinization, and inflammation is essential for targeted therapy. In women, the hypothalamic-pituitary-ovarian axis and adrenal glands are the primary sources of androgens that drive acne pathogenesis.

The Four Pillars of Acne Pathogenesis

Pillar	Mechanism	Hormonal Influence
1. Sebum Overproduction	Sebaceous glands enlarge and produce excess sebum (lipid-rich secretion)	Androgens (testosterone, dihydrotestosterone) directly stimulate sebocyte proliferation and sebum synthesis via androgen receptors
2. Follicular Hyperkeratinization	Abnormal keratinization of the follicular epithelium leads to obstruction of the pilosebaceous duct (microcomedone formation)	Androgens promote keratinocyte proliferation; altered sebum composition (increased squalene, decreased linoleic acid) triggers hyperkeratinization
3. Cutibacterium acnes Colonization	Proliferation of Cutibacterium acnes (formerly Propionibacterium acnes) in the lipid-rich, anaerobic environment of obstructed follicles	Sebum provides nutrients for bacterial growth; hormonal acne creates ideal environment for C. acnes proliferation
4. Inflammation	C. acnes triggers innate immune response via Toll-like receptors, releasing inflammatory cytokines (interleukin-1, tumor necrosis factor-alpha)	Androgens may directly enhance inflammatory cytokine production; inflammatory response determines clinical severity and scarring risk

The Androgen Pathway in Women

Source	Primary Androgens Produced	Contribution to Total Androgens	Clinical Relevance
Ovaries	Testosterone, androstenedione	Approximately 25% of testosterone; 50% of androstenedione	Primary source in PCOS; suppressed by combined oral contraceptives
Adrenal Glands	Dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulfate (DHEAS), androstenedione	Approximately 25% of testosterone; 50% of androstenedione; nearly 100% of DHEAS	Elevated in congenital adrenal hyperplasia; may be sole source after menopause
Peripheral Conversion	Testosterone, dihydrotestosterone (converted in skin, adipose tissue, liver)	Approximately 50% of circulating testosterone	Explains acne with normal serum androgens; local 5-alpha reductase activity is key

Androgen Metabolism in the Pilosebaceous Unit

Key Enzymes in Cutaneous Androgen Metabolism:

5-alpha reductase (Types 1 and 2): Converts testosterone to dihydrotestosterone (DHT), the most potent androgen at the sebaceous gland. Type 1 predominates in sebaceous glands.
17-beta hydroxysteroid dehydrogenase: Converts androstenedione to testosterone in peripheral tissues including skin.
3-beta hydroxysteroid dehydrogenase: Converts DHEA to androstenedione, enabling further metabolism to testosterone.

The sebaceous gland is capable of complete androgen synthesis from adrenal precursors, explaining why women with normal serum androgen levels can still have androgen-driven acne due to increased local enzyme activity or receptor sensitivity.

Key Androgens and Their Role in Acne

Testosterone

Source: Ovaries (25%), adrenals (25%), peripheral conversion (50%)

Action: Binds androgen receptors directly; converted to DHT in target tissues

Clinical relevance: Elevated total or free testosterone suggests ovarian or adrenal source; free testosterone more sensitive than total

Dihydrotestosterone (DHT)

Source: Peripheral conversion from testosterone via 5-alpha reductase

Action: Most potent androgen at sebaceous gland; 5 times greater affinity for androgen receptor than testosterone

Clinical relevance: Not routinely measured; target of spironolactone and finasteride therapy

DHEAS

Source: Almost exclusively adrenal glands

Action: Weak androgen; serves as precursor for peripheral conversion to testosterone

Clinical relevance: Elevated DHEAS indicates adrenal androgen excess; marker for congenital adrenal hyperplasia

Hormonal Regulation Across the Menstrual Cycle

Phase	Dominant Hormones	Effect on Sebaceous Glands	Clinical Manifestation
Follicular Phase (Days 1-14)	Rising estrogen; low progesterone	Estrogen suppresses sebaceous gland activity; anti-androgenic effect	Skin often clearer; acne improvement after menses
Ovulation (Day 14)	Luteinizing hormone surge; peak estrogen	Brief androgen spike from theca cells	Some women experience mid-cycle flares
Luteal Phase (Days 15-28)	Rising progesterone; declining estrogen	Progesterone has mild androgenic activity; sebum production increases	Premenstrual acne flares (days 21-28); most common timing for hormonal acne worsening
Menstruation	Low estrogen and progesterone	Withdrawal of hormonal stimulation	Inflammatory lesions from prior cycle may persist; new lesion formation decreases

How Conditions Cause Hormonal Acne

Condition	Mechanism	Treatment Implication
Polycystic Ovary Syndrome (PCOS)	Ovarian theca cell hyperplasia leads to excess androgen production; insulin resistance amplifies androgen synthesis by stimulating ovarian and adrenal steroidogenesis and reducing sex hormone-binding globulin	Combined oral contraceptives suppress ovarian androgens; anti-androgens (spironolactone) block peripheral effects; metformin improves insulin sensitivity
Non-Classic Congenital Adrenal Hyperplasia	Partial 21-hydroxylase deficiency causes shunting of steroid precursors toward androgen synthesis; elevated 17-hydroxyprogesterone is diagnostic	Low-dose glucocorticoids suppress adrenal androgen production; combined oral contraceptives provide additional benefit
Idiopathic Hyperandrogenism	Elevated androgens without identifiable ovarian or adrenal source; may reflect increased peripheral 5-alpha reductase activity or androgen receptor sensitivity	Anti-androgens (spironolactone) are first-line; combined oral contraceptives provide additive benefit
Androgen-Secreting Tumors	Ovarian or adrenal tumors (rare) produce large amounts of testosterone or DHEAS; rapid onset virilization is characteristic	Surgical excision is definitive; imaging required for localization
Cushing Syndrome	Excess cortisol from pituitary, adrenal, or ectopic source; often associated with adrenal androgen excess	Treatment of underlying cause; acne resolves with cortisol normalization
Hyperprolactinemia	Elevated prolactin stimulates adrenal androgen production (DHEAS); may also cause anovulation and relative estrogen deficiency	Dopamine agonists (cabergoline) normalize prolactin and reduce adrenal androgens
Insulin Resistance (without PCOS)	Hyperinsulinemia stimulates ovarian androgen production and reduces hepatic sex hormone-binding globulin synthesis, increasing free testosterone	Lifestyle modification (weight loss, exercise); metformin may be beneficial
Drug-Induced Hyperandrogenism	Exogenous androgens (testosterone therapy, anabolic steroids), progestins with androgenic activity (levonorgestrel, norethindrone), or discontinuation of anti-androgenic medications	Discontinue offending agent; switch to non-androgenic alternatives

The Protective Role of Estrogen

How Estrogen Protects Against Acne

Estrogen exerts multiple anti-acne effects, which explains why combined oral contraceptives containing ethinyl estradiol are effective for hormonal acne:

Suppresses ovarian androgen production: Estrogen provides negative feedback on luteinizing hormone, reducing ovarian theca cell androgen synthesis
Increases sex hormone-binding globulin (SHBG): Higher SHBG levels bind more circulating testosterone, reducing free (bioactive) testosterone
Opposes androgen action at sebaceous glands: Estrogen receptors in sebocytes may directly antagonize androgen receptor signaling
Reduces sebum production: Direct suppressive effect on sebaceous gland activity independent of androgen blockade

Often Overlooked Mechanism: End-Organ Hypersensitivity

Up to 50% of women with hormonal acne have normal serum androgen levels. This apparent paradox is explained by end-organ hypersensitivity, which includes:

Increased 5-alpha reductase activity: Greater local conversion of testosterone to the more potent dihydrotestosterone within the pilosebaceous unit
Androgen receptor polymorphisms: Genetic variants that increase receptor sensitivity to normal androgen concentrations
Reduced SHBG: Lower binding protein levels result in higher free testosterone fraction despite normal total testosterone

Clinical implication: Normal androgen levels do not exclude a hormonal etiology. Empiric anti-androgen therapy (spironolactone) may still be highly effective in these patients.

The Inflammatory Cascade in Hormonal Acne

Step	Process	Key Mediators
1. Microcomedone Formation	Follicular hyperkeratinization and sebum accumulation create an obstructed, lipid-rich environment	Androgens, altered sebum composition
2. Bacterial Proliferation	Cutibacterium acnes proliferates in the anaerobic, sebum-rich microcomedone	C. acnes lipases, proteases
3. Innate Immune Activation	C. acnes components activate Toll-like receptor 2 on keratinocytes and monocytes	Interleukin-1 alpha and beta, tumor necrosis factor-alpha, interleukin-8
4. Inflammatory Lesion Formation	Neutrophil recruitment, follicular wall rupture, perifollicular inflammation	Matrix metalloproteinases, reactive oxygen species
5. Resolution or Scarring	Healing with or without fibrosis depending on depth and duration of inflammation	Transforming growth factor-beta, collagen remodeling

Why Hormonal Acne Favors the Lower Face

Anatomical Basis for U-Zone Distribution:

The characteristic distribution of hormonal acne along the jawline, chin, and neck reflects the regional variation in androgen receptor density and 5-alpha reductase activity:

Sebaceous glands in the lower face have higher androgen receptor expression compared to the forehead and mid-face
5-alpha reductase type 1 (which converts testosterone to dihydrotestosterone) shows greater activity in the beard area
The lower face and neck represent the androgen-dependent beard distribution in males, explaining why this area is most sensitive to androgen-driven sebum production in women

This anatomical specificity is why the U-zone distribution pattern is highly suggestive of a hormonal etiology, even in the absence of laboratory evidence of hyperandrogenism.

3. History Taking

A comprehensive approach to eliciting the hormonal acne history

Red Flags — Require Urgent Evaluation

Rapid onset virilization — Deepening voice, clitoromegaly, rapid hirsutism suggests androgen-secreting tumor
Severe acne with systemic symptoms — Fever, arthralgias may indicate acne fulminans or SAPHO syndrome
Markedly elevated androgens — Total testosterone greater than 200 ng/dL or DHEAS greater than 700 mcg/dL suggests tumor

Cushing syndrome features — Central obesity, striae, proximal weakness, easy bruising
Galactorrhea with acne — Suggests hyperprolactinemia; evaluate for pituitary adenoma
Prepubertal onset of severe acne — May indicate precocious puberty or adrenal pathology

Systematic History: The “HORMONAL” Approach

Use the mnemonic “HORMONAL” to ensure comprehensive history taking for acne with suspected hormonal etiology:

H — History of acne: When did it start? Adolescent or adult onset? Previous treatments and responses?
O — Other androgen signs: Hirsutism, hair thinning, oily skin? Any voice changes or increased muscle mass?
R — Reproductive history: Menstrual regularity? Fertility issues? Pregnancies? Menopausal status?
M — Medications and supplements: Hormonal contraception? Steroids? Biotin? Protein supplements?
O — Onset and pattern: Where are lesions located? Cyclical flares? Premenstrual worsening?
N — Nutrition and lifestyle: Diet (dairy, high glycemic foods)? Stress levels? Sleep? Exercise?
A — Associated conditions: PCOS diagnosis? Diabetes or insulin resistance? Thyroid disease?
L — Life impact: How does acne affect quality of life? Anxiety, depression, social avoidance?

Targeted Questions by Suspected Cause

Suspected Cause	Key Features	Ask This Question
Polycystic Ovary Syndrome (PCOS)	Irregular periods, hirsutism, obesity, infertility	“Are your periods regular? How many days between cycles? Have you noticed increased facial or body hair?”
Non-Classic Congenital Adrenal Hyperplasia	Early pubarche, short stature, family history, ethnic predisposition (Ashkenazi Jewish, Hispanic, Mediterranean)	“Did you develop pubic hair or body odor before age 8? Is there a family history of infertility or ambiguous genitalia?”
Androgen-Secreting Tumor	Rapid onset (weeks to months), severe virilization, markedly elevated androgens	“How quickly did these symptoms develop? Have you noticed voice deepening, increased muscle bulk, or clitoral enlargement?”
Cushing Syndrome	Central obesity, moon facies, striae, proximal weakness, hypertension	“Have you gained weight primarily around your abdomen? Do you bruise easily? Have you noticed purple stretch marks?”
Hyperprolactinemia	Galactorrhea, amenorrhea, headaches, visual changes	“Have you noticed any breast discharge? Any headaches or changes in your vision?”
Thyroid Dysfunction	Weight changes, fatigue, temperature intolerance, skin changes	“Have you experienced unexplained weight changes, fatigue, or feeling unusually hot or cold?”
Insulin Resistance	Central obesity, acanthosis nigricans, family history of type 2 diabetes	“Have you noticed darkening of the skin around your neck or underarms? Is there diabetes in your family?”
Drug-Induced Acne	Temporal relationship to medication initiation, monomorphic eruption	“When did you start any new medications? This includes supplements, vitamins, and anything you buy over the counter.”
Post-Pill Acne	Onset within 3-6 months of stopping combined oral contraceptives	“Have you recently stopped birth control pills? How long ago did you stop them?”
Perimenopausal Acne	Age 45-55, irregular cycles, vasomotor symptoms	“Are you experiencing hot flashes, night sweats, or changes in your menstrual pattern?”

Detailed Acne History

Characterize the Acne

Onset: Age at first appearance; adolescent versus adult onset
Duration: How long has current episode lasted?
Location: Where are lesions concentrated? Lower face (hormonal) versus T-zone (classic)?
Lesion types: Predominantly inflammatory (papules, pustules, nodules) or comedonal?
Severity progression: Stable, worsening, or improving?
Scarring: Any post-inflammatory hyperpigmentation or scarring?

Treatment History

Topical therapies: Retinoids, benzoyl peroxide, antibiotics — duration and response
Oral antibiotics: Which ones? How long? Any improvement?
Hormonal therapies: Combined oral contraceptives, spironolactone — response?
Isotretinoin: Previous courses? Cumulative dose? Relapse timing?
Procedures: Chemical peels, laser, extraction — results?
Over-the-counter products: Skincare routine details

Menstrual and Reproductive History

Question	Why It Matters	Red Flag Finding
Age at menarche	Early menarche may indicate early androgen exposure	Menarche before age 9 or after age 16
Cycle length and regularity	Oligomenorrhea (cycles greater than 35 days) suggests anovulation, common in PCOS	Fewer than 9 cycles per year; cycles greater than 45 days
Duration and flow	Heavy or prolonged bleeding may indicate anovulatory cycles	Bleeding greater than 7 days; flooding or clots
Premenstrual acne flares	Strong indicator of hormonal etiology	Not a red flag, but supports hormonal diagnosis
Contraceptive history	Type of contraception affects androgen levels	Acne worsening on progestin-only methods or after stopping pills
Pregnancy history	Difficulty conceiving suggests anovulation	Infertility greater than 12 months; recurrent pregnancy loss
Menopausal status	Perimenopausal hormone changes can trigger acne	New acne with vasomotor symptoms in appropriate age group

Medication and Supplement History

Medications That Can Cause or Worsen Acne

Corticosteroids — Systemic or high-potency topical; causes steroid acne (monomorphic papulopustules)
Androgens and anabolic steroids — Testosterone therapy, DHEA supplements, bodybuilding steroids
Progestins with androgenic activity — Levonorgestrel, norethindrone, norgestrel (in some contraceptives)
Lithium — Can induce or exacerbate acne
Anticonvulsants — Phenytoin, phenobarbital, carbamazepine
Isoniazid — Antitubercular medication
Cyclosporine — Immunosuppressant
Epidermal growth factor receptor inhibitors — Cetuximab, erlotinib (acneiform eruption)

Supplements and Other Products

Biotin (vitamin B7) — High doses (greater than 5 mg daily) commonly cause acne
Vitamin B6 and B12 — Can trigger acneiform eruptions in high doses
Whey protein supplements — Associated with acne, possibly via insulin-like growth factor-1
DHEA supplements — Direct androgen precursor
Iodine-containing supplements — Kelp, seaweed extracts
Comedogenic skincare products — Oils, heavy moisturizers, certain sunscreens
Hair products — Pomades, oils (pomade acne along hairline)

Social and Lifestyle History

Factor	Relevance to Hormonal Acne	Key Questions
Diet	High glycemic index foods and dairy may worsen acne via insulin and insulin-like growth factor-1 pathways	“Do you consume a lot of sugary foods, white bread, or dairy products? Have you noticed any dietary triggers?”
Stress	Chronic stress increases cortisol and adrenal androgens; stress also triggers skin picking behaviors	“How would you rate your stress level? Do you notice acne worsening during stressful periods?”
Sleep	Sleep deprivation affects cortisol rhythm and insulin sensitivity	“How many hours of sleep do you get? Do you have trouble falling or staying asleep?”
Exercise	Regular exercise improves insulin sensitivity; however, excessive exercise and anabolic steroid use worsen acne	“How often do you exercise? Do you use any performance-enhancing supplements?”
Occupation	Exposure to oils, greases, or occlusive equipment can cause occupational acne	“What do you do for work? Are you exposed to oils, chemicals, or do you wear protective equipment on your face?”
Skincare habits	Over-washing, harsh products, or comedogenic cosmetics can worsen acne	“Walk me through your daily skincare routine. What products do you use on your face?”
Smoking	Controversial association; may promote comedonal acne through effects on sebum composition	“Do you smoke or use tobacco products?”

Family History

Important Family History Questions

Acne: Family history of severe or persistent acne (strong genetic component)
PCOS: Mother or sisters with irregular periods, hirsutism, infertility, or diagnosed PCOS
Congenital adrenal hyperplasia: Family history of ambiguous genitalia, early puberty, infertility, or short stature
Type 2 diabetes: First-degree relatives with diabetes (indicates genetic predisposition to insulin resistance)
Premature balding: Male relatives with early androgenic alopecia (suggests familial androgen sensitivity)
Hirsutism: Female relatives with excessive hair growth

Psychosocial Assessment

Screen for Psychological Impact

Acne can have significant psychological consequences that may be disproportionate to clinical severity. Screen all patients for:

Depression: “Have you been feeling down, depressed, or hopeless?”
Anxiety: “Do you feel nervous or anxious about your skin? Does it affect your social activities?”
Body dysmorphic disorder: “Do you spend a lot of time examining or trying to hide your skin? Do others seem less bothered by your skin than you are?”
Skin picking (excoriation disorder): “Do you pick at your skin? Is it hard to stop even when you want to?”
Suicidal ideation: Consider screening especially if considering isotretinoin (though causal link is debated)

Important: Severe psychological distress warrants earlier and more aggressive treatment, and may require referral for mental health support.

4. Physical Examination

A systematic approach for hormonal acne evaluation

Systematic Framework: The physical examination for hormonal acne extends beyond the skin to identify signs of underlying endocrine disorders. Use the “Skin-to-System” approach: start with detailed skin examination, then systematically evaluate for signs of hyperandrogenism and associated conditions.

General Inspection

Body habitus: Central obesity (waist circumference greater than 88 cm) suggests insulin resistance and PCOS; truncal obesity with thin extremities may indicate Cushing syndrome
Fat distribution: Android (apple-shaped) versus gynoid (pear-shaped) distribution
Overall appearance: Signs of virilization including masculine body build, increased muscle mass
Skin quality: Oily skin (seborrhea) affecting face and scalp supports androgen excess
Affect and demeanor: Signs of psychological distress, anxiety, or depression

Vital Signs

Vital Sign	What to Look For	Clinical Significance
Blood Pressure	Hypertension (greater than 130/80 mmHg)	Associated with PCOS, insulin resistance, Cushing syndrome; important for spironolactone monitoring
Heart Rate	Tachycardia or bradycardia	May suggest thyroid dysfunction
Body Mass Index	Calculate from height and weight; BMI greater than 25 is overweight, greater than 30 is obese	Obesity worsens insulin resistance and hyperandrogenism; affects treatment choices
Waist Circumference	Measure at level of iliac crest; greater than 88 cm (35 inches) in women is abnormal	Central adiposity is a key marker of metabolic syndrome and insulin resistance

Detailed Skin Examination

Acne Assessment

Parameter	What to Document	Clinical Implications
Distribution	Map affected areas: U-zone (jawline, chin, neck), T-zone (forehead, nose), cheeks, trunk	U-zone predominance strongly suggests hormonal etiology
Lesion types	Count and describe: open comedones, closed comedones, papules, pustules, nodules, cysts	Inflammatory predominance (papules, pustules, nodules) typical of hormonal acne
Severity grading	Use standardized scale (mild, moderate, severe) or lesion counts	Guides treatment intensity and need for specialist referral
Scarring	Ice pick, boxcar, rolling scars; keloids; post-inflammatory hyperpigmentation	Presence of scarring indicates need for more aggressive treatment to prevent progression
Excoriations	Evidence of skin picking: linear erosions, crusts in various stages of healing	Suggests acne excoriée; requires behavioral intervention alongside acne treatment

Signs of Hyperandrogenism on Skin

Hirsutism

Assess for terminal (coarse, pigmented) hair in androgen-dependent areas using the modified Ferriman-Gallwey score:

Upper lip
Chin
Chest
Upper and lower back
Upper and lower abdomen
Upper arms
Thighs

Score interpretation: Score of 8 or greater indicates hirsutism (lower thresholds may apply in certain ethnic groups)

Other Cutaneous Signs

Seborrhea: Oily skin, especially on face and scalp
Androgenic alopecia: Diffuse thinning at crown and frontal hairline with preserved frontal hairline (female pattern); widening of central part
Acanthosis nigricans: Velvety, hyperpigmented plaques in skin folds (neck, axillae, groin) — indicates insulin resistance
Skin tags (acrochordons): Often associated with insulin resistance
Striae: Purple or violaceous striae suggest Cushing syndrome; white striae are non-specific

Head and Neck Examination

Structure	What to Assess	Abnormal Findings and Significance
Scalp and Hair	Hair density, pattern of loss, hair quality	Female pattern hair loss (central thinning with frontal preservation) suggests hyperandrogenism
Face	Facial plethora, moon facies, facial hair	Moon facies with plethora suggests Cushing syndrome; terminal facial hair indicates hirsutism
Eyes	Visual fields (by confrontation), eye movements	Bitemporal hemianopia suggests pituitary macroadenoma (prolactinoma or other)
Thyroid	Size, nodules, tenderness	Goiter or nodules warrant thyroid function testing
Neck skin	Posterior neck, lateral neck folds	Acanthosis nigricans at posterior neck is classic location; indicates insulin resistance
Voice	Pitch, quality	Voice deepening is a sign of significant virilization; suggests androgen-secreting tumor

Breast Examination

Breast development: Assess Tanner stage if appropriate
Galactorrhea: Gently express nipples to check for discharge — milky discharge suggests hyperprolactinemia
Breast atrophy: May indicate significant androgen excess with estrogen deficiency

Abdominal Examination

Central adiposity: Measure waist circumference at iliac crest level
Striae: Wide, purple/violaceous striae on abdomen suggest Cushing syndrome; thin white striae are non-specific
Hepatomegaly: May indicate non-alcoholic fatty liver disease associated with insulin resistance
Adnexal masses: Palpable ovarian enlargement is uncommon but may indicate ovarian tumor or severe polycystic ovaries
Acanthosis nigricans: Check inguinal folds and umbilical area

Extremities Examination

Acanthosis nigricans: Check axillae, antecubital fossae, knuckles
Skin tags: Often found in axillae; associated with insulin resistance
Muscle mass: Increased muscle bulk may indicate androgen excess; proximal muscle weakness suggests Cushing syndrome
Edema: Peripheral edema may be relevant if considering spironolactone therapy
Hirsutism: Assess hair on forearms and lower legs (less androgen-sensitive but may be affected in severe cases)

External Genitalia (If Indicated)

When to Perform Genital Examination

External genital examination is indicated when there is clinical suspicion for significant virilization or when symptoms suggest gynecologic pathology:

Clitoromegaly: Clitoral length greater than 10 mm or glans width greater than 7 mm suggests severe androgen excess (tumor, exogenous androgens)
Labial fusion: May indicate early androgen exposure
Pubic hair pattern: Male-pattern escutcheon (diamond-shaped extending toward umbilicus) versus female pattern (inverted triangle)

Clitoromegaly is a red flag for androgen-secreting tumor and warrants urgent investigation.

Expected Findings by Etiology

Condition	Skin Findings	Body Habitus	Other Findings
PCOS	Acne (U-zone), hirsutism, acanthosis nigricans, androgenic alopecia	Often central obesity; can be normal weight	May have palpably enlarged ovaries (uncommon)
Non-Classic Congenital Adrenal Hyperplasia	Similar to PCOS: acne, hirsutism	May be shorter than expected; otherwise variable	Often indistinguishable from PCOS on examination alone
Androgen-Secreting Tumor	Severe acne, marked hirsutism, androgenic alopecia, clitoromegaly	Rapid masculinization	Voice deepening, increased muscle mass, possible palpable mass
Cushing Syndrome	Acne, facial plethora, thin skin, easy bruising, purple striae	Central obesity, moon facies, dorsocervical fat pad (buffalo hump)	Proximal muscle weakness, hypertension
Hyperprolactinemia	Acne, may have hirsutism	Usually normal	Galactorrhea, visual field defects if macroadenoma
Idiopathic/End-Organ Sensitivity	Acne (U-zone pattern)	Usually normal	Normal examination; diagnosis of exclusion
Drug-Induced	Monomorphic papulopustular eruption (steroid acne); distribution may be atypical	Depends on causative medication	Temporal relationship to medication

Important Teaching Point

Normal physical examination is common! Many women with hormonal acne have completely normal physical examinations. The absence of hirsutism, obesity, or acanthosis nigricans does not exclude a hormonal etiology.

Key points to remember:

Up to 50% of women with hormonal acne have normal serum androgen levels and normal physical findings
The U-zone distribution pattern itself is the most important clinical clue
Lean women with PCOS may have no visible signs other than acne and menstrual irregularity
End-organ hypersensitivity to androgens cannot be detected on physical examination
A normal examination does not preclude the need for laboratory evaluation or a trial of hormonal therapy

Physical Examination Checklist

Quick Reference Checklist for Hormonal Acne Evaluation:

Record vital signs including blood pressure, BMI, and waist circumference
Characterize acne: distribution, lesion types, severity, scarring
Assess for hirsutism using modified Ferriman-Gallwey score
Examine scalp for androgenic alopecia pattern
Look for acanthosis nigricans (neck, axillae, groin)
Check for skin tags
Assess body habitus and fat distribution
Examine for striae (note color: purple versus white)
Palpate thyroid
Express nipples for galactorrhea if indicated
Consider external genital examination if virilization suspected

5. Differential Diagnosis

Systematic approach organized by probability and clinical features

When evaluating a woman with acne that appears hormonal in pattern, the differential diagnosis encompasses two distinct considerations: first, confirming that the skin findings represent true acne vulgaris rather than an acne mimicker; and second, identifying the underlying hormonal or non-hormonal cause driving the acne. This systematic approach ensures accurate diagnosis and appropriate treatment selection.

Step 1: Is This Really Acne?

Before attributing acne to hormonal causes, first confirm the diagnosis of acne vulgaris. Several conditions can mimic acne and require different treatment approaches:

Condition	Key Distinguishing Features	Distribution	How to Differentiate
Acne Vulgaris (True Acne)	Comedones present (open and/or closed); mixed lesion types; responds to retinoids	Face, chest, back; hormonal pattern favors U-zone	Presence of comedones is the key feature distinguishing acne from mimickers
Rosacea	No comedones; flushing and telangiectasias; sensitive skin; triggers (alcohol, heat, spicy food)	Central face (cheeks, nose, chin); spares periocular area	Look for background erythema, telangiectasias; ask about flushing triggers
Perioral Dermatitis	No comedones; grouped papulopustules; often history of topical steroid use	Perioral with sparing of vermilion border; may extend to perinasal and periocular	Characteristic sparing of skin immediately adjacent to lips; steroid history
Folliculitis	No comedones; monomorphic pustules centered on hair follicles; may be pruritic	Any hair-bearing area; often trunk, buttocks, thighs	Lesions uniformly follicular; bacterial culture if suspected; may be Gram-negative
Gram-Negative Folliculitis	Sudden worsening of acne after prolonged antibiotic use; superficial pustules or deep nodules	Perinasal and central face	History of long-term oral antibiotics; bacterial culture shows Gram-negative organisms
Pityrosporum (Malassezia) Folliculitis	No comedones; monomorphic pruritic papulopustules; worsens with antibiotics	Upper trunk, shoulders, upper arms; may involve face	Pruritus is prominent; worsens with antibiotics; responds to antifungals
Acneiform Drug Eruption	No comedones; monomorphic; abrupt onset temporally related to medication	May extend beyond typical acne distribution	Medication history; monomorphic appearance; rapid onset
Hidradenitis Suppurativa	Double comedones; deep nodules and sinus tracts; chronic scarring	Axillae, groin, inframammary; not typical acne distribution	Location in apocrine gland-bearing areas; sinus tracts; double comedones
Demodex Folliculitis	No comedones; erythematous papulopustules; rosacea-like	Central face, perioral	Skin scraping for Demodex mites; often in immunocompromised

Step 2: What Is Causing the Hormonal Acne?

Step-by-Step Approach to Identifying the Underlying Cause:

Step 1: Rule out drug-induced acne — Review all medications and supplements
Step 2: Assess for clinical hyperandrogenism — Hirsutism, androgenic alopecia, menstrual irregularity
Step 3: Consider PCOS first — Most common endocrine cause in reproductive-age women
Step 4: Exclude other endocrine disorders — Congenital adrenal hyperplasia, Cushing syndrome, tumors
Step 5: If workup negative — Consider idiopathic hyperandrogenism or end-organ hypersensitivity

Differential Diagnosis by Probability

Probability	Condition	Approximate Frequency	Key Distinguishing Features
COMMON (approximately 80%)	Polycystic Ovary Syndrome (PCOS)	60-70% of hormonal acne cases	Oligomenorrhea, hirsutism, obesity, infertility; elevated testosterone or clinical hyperandrogenism
	Idiopathic Hyperandrogenism	10-15%	Elevated androgens without PCOS criteria; regular menses; no polycystic ovaries
	End-Organ Hypersensitivity	10-15%	Normal androgens, normal menses; hormonal acne pattern; responds to anti-androgens
	Drug-Induced Acne	5-10%	Temporal relationship to offending medication; may have atypical distribution
LESS COMMON (approximately 15%)	Non-Classic Congenital Adrenal Hyperplasia (21-Hydroxylase Deficiency)	1-10% (varies by ethnicity)	Similar to PCOS; may have shorter stature; elevated 17-hydroxyprogesterone
	Hyperprolactinemia	2-5%	Galactorrhea, amenorrhea, headaches; elevated prolactin
	Thyroid Dysfunction	2-5%	Hypothyroidism or hyperthyroidism symptoms; altered sex hormone-binding globulin
	Insulin Resistance (without PCOS)	Variable	Acanthosis nigricans, central obesity; may have normal androgens but low SHBG
UNCOMMON BUT SERIOUS (less than 5%)	Androgen-Secreting Ovarian Tumor	Less than 1%	Rapid virilization; testosterone typically greater than 200 ng/dL; pelvic mass
	Androgen-Secreting Adrenal Tumor	Less than 1%	Rapid virilization; markedly elevated DHEAS (greater than 700 mcg/dL); adrenal mass
	Cushing Syndrome	Less than 1%	Central obesity, striae, moon facies, proximal weakness; elevated cortisol
	Acromegaly	Rare	Coarsening of facial features, enlarged hands and feet; elevated IGF-1

Differential Diagnosis by Age Group

Age Group	Most Likely Causes	Key Considerations
Adolescent (12-18 years)	Physiological (pubertal) acne; PCOS (if other features present)	Allow 2-3 years post-menarche for cycle regulation before diagnosing PCOS; severe acne may warrant earlier evaluation
Young Adult (18-25 years)	PCOS; idiopathic hyperandrogenism; non-classic CAH	Peak age for PCOS diagnosis; consider CAH if symptoms since puberty
Reproductive Age (25-40 years)	PCOS; end-organ hypersensitivity; drug-induced	Late-onset acne warrants hormonal evaluation; post-pill acne common
Perimenopausal (40-55 years)	Perimenopausal hormonal changes; relative androgen excess	Declining estrogen with stable androgens; exclude ovarian pathology
Postmenopausal (greater than 55 years)	Adrenal androgens; androgen-secreting tumor (higher suspicion)	New-onset acne in postmenopausal women warrants thorough evaluation for tumor

Etiological Approach by Source of Androgen Excess

Ovarian Causes

Polycystic ovary syndrome

Ovarian hyperthecosis

Androgen-secreting ovarian tumors (Sertoli-Leydig, hilus cell)

Ovarian stromal hyperplasia

Adrenal Causes

Non-classic congenital adrenal hyperplasia

Androgen-secreting adrenal tumors

Cushing syndrome

Adrenal carcinoma

Peripheral/End-Organ Causes

Increased 5-alpha reductase activity

Androgen receptor hypersensitivity

Decreased sex hormone-binding globulin

Obesity (increased peripheral conversion)

Other/Mixed Causes

Drug-induced hyperandrogenism

Hyperprolactinemia

Thyroid dysfunction

Acromegaly

Drug-Induced Acne: Comprehensive List

Drug or Drug Class	Mechanism	Characteristics	Time to Resolution After Stopping
Corticosteroids (systemic)	Follicular proliferation; immunosuppression favoring C. acnes	Monomorphic papulopustules; trunk predominant; no comedones (“steroid acne”)	2-4 weeks after stopping or dose reduction
Anabolic steroids	Direct androgenic stimulation of sebaceous glands	Severe nodulocystic acne; trunk involvement; often with other virilization	Weeks to months; may cause permanent scarring
Testosterone therapy	Androgenic stimulation	Acne in typical hormonal distribution; dose-dependent	Weeks to months after stopping or dose reduction
Progestins (androgenic)	Levonorgestrel, norethindrone have androgenic activity	May worsen or trigger acne; typically within first few months	2-3 months after switching to non-androgenic progestin
Progestin-only contraceptives	Lack of estrogen’s protective effect; some progestins are androgenic	Includes depot medroxyprogesterone, progestin-only pills, hormonal IUDs	Variable; may need to switch to combined method
DHEA supplements	Direct androgen precursor	Acne with other androgenic effects; dose-dependent	2-4 weeks
Lithium	Uncertain; may affect follicular keratinization	Inflammatory acne; may be resistant to treatment	Weeks to months; may persist
Phenytoin	Uncertain; may alter hormone metabolism	Comedonal and inflammatory acne	Weeks after stopping
Isoniazid	Uncertain mechanism	Acneiform eruption	Resolves after treatment completion
Cyclosporine	Sebaceous gland hypertrophy	Comedonal acne; hypertrichosis often present	Weeks to months
EGFR inhibitors	Disruption of epidermal growth factor signaling in follicles	Papulopustular eruption (not true acne); face and trunk	Resolves with dose reduction or stopping
Biotin (high dose)	Uncertain; possibly affects keratinocyte proliferation	Inflammatory acne; common with doses greater than 5 mg daily	2-4 weeks
Vitamin B12	Alters C. acnes gene expression, increasing porphyrin production	Inflammatory acne; may worsen existing acne	2-4 weeks
Whey protein	Increases insulin and IGF-1 levels	Inflammatory acne; common in athletes	2-4 weeks after stopping

Quick Reference: “If You See This, Think This”

Clinical Clue	Think This First	Next Step
U-zone acne + irregular periods + hirsutism	Polycystic ovary syndrome	Check testosterone, DHEAS, pelvic ultrasound
Acne + galactorrhea + amenorrhea	Hyperprolactinemia	Check prolactin level; if elevated, pituitary MRI
Rapid-onset severe acne + virilization	Androgen-secreting tumor	Urgent testosterone and DHEAS; imaging if elevated
Acne + central obesity + purple striae	Cushing syndrome	24-hour urinary free cortisol or overnight dexamethasone suppression test
Acne starting after new medication	Drug-induced acne	Review medication list; consider stopping or switching
Acne worsening after stopping birth control	Post-pill acne (unmasked PCOS or rebound)	Evaluate for PCOS; consider restarting hormonal therapy
Acne + elevated 17-OHP + ethnic risk	Non-classic congenital adrenal hyperplasia	ACTH stimulation test for confirmation
Hormonal acne pattern + normal hormones + normal exam	End-organ hypersensitivity	Empiric trial of spironolactone
Acne + acanthosis nigricans + obesity	Insulin resistance (with or without PCOS)	Fasting glucose and insulin; consider metformin
Monomorphic papulopustules + no comedones + trunk	Not acne — consider steroid acne, folliculitis, Malassezia	Detailed history; consider culture or KOH prep

Red Flags Suggesting Serious Underlying Pathology

Rapid progression (weeks to months) of acne with virilization → Androgen-secreting tumor
Total testosterone greater than 200 ng/dL → Ovarian or adrenal tumor
DHEAS greater than 700 mcg/dL → Adrenal tumor or carcinoma
Voice deepening, clitoromegaly → Severe androgen excess; tumor likely
Cushingoid features (moon facies, buffalo hump, striae) → Cushing syndrome
New acne in postmenopausal woman → Higher suspicion for ovarian pathology

6. Diagnostic Investigations

A stepwise, cost-effective approach guided by clinical suspicion

When Is Laboratory Evaluation Indicated?

Not all women with acne require laboratory testing. Consider hormonal evaluation in the following situations:

Acne with hormonal pattern (U-zone distribution, premenstrual flares)
Acne resistant to conventional topical and oral antibiotic therapy
Clinical signs of hyperandrogenism (hirsutism, androgenic alopecia)
Menstrual irregularity (oligomenorrhea, amenorrhea)
Late-onset acne (new acne after age 25)
Rapid onset of severe acne with signs of virilization
Acne recurring after isotretinoin treatment
Before initiating hormonal therapy (baseline evaluation)

Optimal Timing for Hormone Testing

For accurate interpretation, blood samples should ideally be drawn:

Early follicular phase: Days 2-5 of menstrual cycle (preferred for androgens)
Fasting state: For glucose, insulin, and lipid testing
Morning: 8-10 AM for cortisol and DHEAS (diurnal variation)
Off hormonal contraception: Ideally 2-3 months after stopping for accurate androgen assessment (though not always practical)

Note: If menstrual cycles are irregular or absent, testing can be done at any time, as these women are typically anovulatory.

First-Line Investigations for Suspected Hormonal Acne

Investigation	Purpose	What to Look For	Practical Points
Total Testosterone	Screen for ovarian and adrenal androgen excess	Normal: 15-70 ng/dL; mildly elevated in PCOS; markedly elevated (greater than 200 ng/dL) suggests tumor	Draw in early morning; can be normal in hormonal acne due to end-organ sensitivity
Free Testosterone	More sensitive marker of bioavailable androgen	Elevated free testosterone with normal total testosterone suggests low SHBG	Calculate free testosterone or measure directly; more sensitive than total testosterone
Sex Hormone-Binding Globulin (SHBG)	Assess bioavailable testosterone; marker of insulin resistance	Low SHBG (less than 30 nmol/L) increases free testosterone; associated with insulin resistance	Low SHBG explains hyperandrogenism even with normal total testosterone
Dehydroepiandrosterone Sulfate (DHEAS)	Marker of adrenal androgen production	Normal: 35-430 mcg/dL (varies by age); elevated suggests adrenal source; greater than 700 mcg/dL suggests tumor	Almost exclusively adrenal origin; stable throughout day (unlike DHEA)
Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH)	Assess gonadotropin ratio; evaluate for PCOS	LH:FSH ratio greater than 2:1 supports PCOS diagnosis (though not required by Rotterdam criteria)	Draw in follicular phase; ratio less reliable if on hormonal contraception
Prolactin	Screen for hyperprolactinemia	Normal: less than 25 ng/mL; mild elevation common with PCOS; marked elevation suggests prolactinoma	Stress can elevate; repeat if mildly elevated; draw before breast examination
Thyroid-Stimulating Hormone (TSH)	Screen for thyroid dysfunction	Hypothyroidism can affect menstrual cycles and SHBG levels	Routine screening; low yield but easy to exclude

Second-Line Investigations by Clinical Suspicion

If Suspecting Polycystic Ovary Syndrome

Laboratory Tests

Anti-Müllerian hormone (AMH): Elevated (greater than 4.7 ng/mL) correlates with polycystic ovarian morphology; useful if ultrasound unavailable
Fasting glucose and insulin: Calculate HOMA-IR; assess for insulin resistance
Lipid panel: Screen for metabolic syndrome (common in PCOS)
Hemoglobin A1c: Screen for prediabetes or diabetes

Imaging

Pelvic ultrasound (transvaginal preferred): Polycystic ovarian morphology defined as 12 or more follicles (2-9 mm) per ovary OR ovarian volume greater than 10 mL
Note: Ultrasound findings alone are not diagnostic; 20-30% of normal women have polycystic-appearing ovaries
Updated threshold (2018 guidelines): Some recommend 20 or more follicles per ovary with modern ultrasound technology

Rotterdam Criteria for PCOS Diagnosis

Diagnosis requires 2 of 3 criteria (after excluding other causes):

Oligo-ovulation or anovulation — Irregular cycles (greater than 35 days) or amenorrhea
Clinical and/or biochemical hyperandrogenism — Hirsutism, acne, alopecia OR elevated testosterone
Polycystic ovarian morphology on ultrasound — Or elevated AMH as surrogate

Important: Acne alone can satisfy the hyperandrogenism criterion if it is moderate-to-severe or has a clearly hormonal pattern.

If Suspecting Non-Classic Congenital Adrenal Hyperplasia

First-Line Test

17-Hydroxyprogesterone (17-OHP): Draw in early morning, follicular phase
Interpretation:
- Less than 200 ng/dL: CAH unlikely
- 200-1000 ng/dL: Indeterminate; requires ACTH stimulation test
- Greater than 1000 ng/dL: Highly suggestive of non-classic CAH

Confirmatory Test

ACTH (cosyntropin) stimulation test: Measure 17-OHP at baseline and 60 minutes after 250 mcg IV cosyntropin
Diagnostic threshold: Stimulated 17-OHP greater than 1000-1500 ng/dL confirms 21-hydroxylase deficiency
Genetic testing: CYP21A2 gene analysis available for confirmation

If Suspecting Androgen-Secreting Tumor

Urgent Workup for Suspected Tumor

Order these tests immediately if rapid virilization or markedly elevated androgens:

Total testosterone: Greater than 200 ng/dL strongly suggests ovarian tumor
DHEAS: Greater than 700 mcg/dL strongly suggests adrenal tumor

Imaging:

Pelvic ultrasound or MRI: For suspected ovarian source
CT or MRI of adrenal glands: For suspected adrenal source (elevated DHEAS)

Note: Small ovarian tumors may not be visible on imaging; consider ovarian vein sampling or exploratory surgery if clinical suspicion remains high despite negative imaging.

If Suspecting Cushing Syndrome

Screening Tests (Any One)

24-hour urinary free cortisol: Collect complete 24-hour sample; elevated if greater than 3 times upper limit of normal
Overnight 1 mg dexamethasone suppression test: Take 1 mg dexamethasone at 11 PM; check 8 AM cortisol. Cortisol greater than 1.8 mcg/dL is positive
Late-night salivary cortisol: Collect at 11 PM; elevated levels suggest loss of diurnal rhythm

Further Workup

Two positive screening tests warrant referral to endocrinology
Additional testing to determine ACTH-dependent versus ACTH-independent cause
Imaging (pituitary MRI, adrenal CT) based on ACTH levels

If Suspecting Hyperprolactinemia

Confirm Elevation

Repeat fasting prolactin: In relaxed state; avoid breast examination before draw
Degree of elevation guides workup:
- 25-50 ng/mL: May be stress, medications, or microprolactinoma
- 50-200 ng/mL: Likely prolactinoma
- Greater than 200 ng/mL: Macroprolactinoma very likely

Imaging

Pituitary MRI with gadolinium: For confirmed hyperprolactinemia
Visual field testing: If macroadenoma present or suspected
Rule out medications: Antipsychotics, metoclopramide, and others cause drug-induced hyperprolactinemia

Pre-Treatment Baseline Investigations

Planned Treatment	Required Baseline Tests	Purpose
Combined Oral Contraceptives	Blood pressure; personal and family history screen for thromboembolism	Assess contraindications (migraine with aura, thrombophilia, hypertension, smoking after age 35)
Spironolactone	Potassium, creatinine; pregnancy test	Baseline renal function; hyperkalemia risk; teratogenic (feminization of male fetus)
Isotretinoin	Pregnancy test; liver function tests; fasting lipid panel; CBC	Absolute contraindication in pregnancy; monitor for hepatotoxicity and hypertriglyceridemia
Metformin	Creatinine, eGFR; liver function tests; vitamin B12 (if long-term use anticipated)	Contraindicated if eGFR less than 30; caution if 30-45

Empiric Treatment Trials as Diagnostic Tools

When Laboratory Evaluation Is Normal

If laboratory evaluation is unrevealing but clinical presentation suggests hormonal acne, empiric therapy can serve as both treatment and diagnostic tool:

Trial of combined oral contraceptive: Use formulation with anti-androgenic progestin (drospirenone, norgestimate). Response within 3-6 months supports hormonal etiology.
Trial of spironolactone: Start 50-100 mg daily, titrate to 100-200 mg. Response supports androgen-mediated mechanism even with normal serum levels.
Combination therapy: Combined oral contraceptive plus spironolactone often most effective for hormonal acne.

Expected timeline: Allow 3-6 months for full response; initial improvement may be seen at 6-8 weeks.

Summary: Stepwise Investigation Approach

Step 1: Determine if hormonal evaluation is indicated (see criteria above)

Step 2: Order first-line tests: Total testosterone (or free testosterone), DHEAS, prolactin, TSH

Step 3: Based on results:

Elevated testosterone, menstrual irregularity: Order pelvic ultrasound, LH/FSH, fasting glucose/insulin → Evaluate for PCOS
Elevated DHEAS or 17-OHP: Consider non-classic CAH → ACTH stimulation test
Markedly elevated testosterone (greater than 200 ng/dL) or DHEAS (greater than 700 mcg/dL): Urgent imaging for tumor
Elevated prolactin: Pituitary MRI if confirmed
Cushingoid features: Screening tests for Cushing syndrome
All tests normal: Consider end-organ hypersensitivity; proceed with empiric hormonal therapy

7. Pattern Recognition and Clinical Decision-Making

Practical algorithms and decision pathways

Step 1: Is This Urgent?

Clinical Scenario	Urgency Level	Immediate Action
Rapid virilization (weeks to months): voice deepening, clitoromegaly, rapid hirsutism, severe acne	EMERGENT	Same-day testosterone and DHEAS; urgent imaging if elevated; endocrinology and gynecologic oncology referral
Severe nodulocystic acne with systemic symptoms (fever, arthralgias)	EMERGENT	Consider acne fulminans; urgent dermatology referral; may require systemic corticosteroids
Acne with suicidal ideation or severe depression	EMERGENT	Mental health crisis assessment; psychiatric referral; expedite acne treatment
Cushingoid features with acne	URGENT	Cushing syndrome screening within 1-2 weeks; endocrinology referral if positive
Severe scarring acne not responding to oral antibiotics	URGENT	Expedite hormonal therapy or isotretinoin referral to prevent permanent scarring
New-onset acne in postmenopausal woman	URGENT	Complete hormonal workup within 2 weeks; pelvic imaging to exclude ovarian pathology
Hormonal acne pattern with menstrual irregularity	ROUTINE	Schedule hormonal evaluation; initiate workup for PCOS
Mild-moderate hormonal acne, regular menses	ROUTINE	Consider empiric hormonal therapy; laboratory testing optional

Step 2: Classify by Severity and Clinical Features

Mild Hormonal Acne

Few papules and pustules; U-zone distribution; minimal scarring risk

Proceed to: Algorithm A

Moderate Hormonal Acne

Multiple inflammatory lesions; possible early scarring; affecting quality of life

Proceed to: Algorithm B

Severe Hormonal Acne

Nodules, cysts present; scarring; significant psychosocial impact

Proceed to: Algorithm C

Step 3: Follow the Appropriate Algorithm

Algorithm A: Mild Hormonal Acne

Clinical Scenario	First-Line Approach	If Inadequate Response (12 weeks)
Mild acne, desires contraception	Combined oral contraceptive with anti-androgenic progestin (drospirenone, norgestimate) + topical retinoid	Add spironolactone 50-100 mg daily
Mild acne, contraception not needed or contraindicated	Topical retinoid + benzoyl peroxide; consider spironolactone if hormonal pattern clear	Add or increase spironolactone to 100 mg daily
Mild acne, premenstrual flares only	Continuous combined oral contraceptive (skip placebo week) + topical therapy	Add spironolactone; consider perimenstrual topical intensification

Algorithm B: Moderate Hormonal Acne

Clinical Scenario	First-Line Approach	If Inadequate Response (12-16 weeks)
Moderate acne + PCOS or hyperandrogenism	Combined oral contraceptive + spironolactone 100 mg daily + topical retinoid	Increase spironolactone to 150-200 mg; if still inadequate, consider isotretinoin referral
Moderate acne, failed topical therapy	Combined oral contraceptive + spironolactone 100 mg + topical retinoid	Increase spironolactone; add short-course oral antibiotic for acute flare
Moderate acne, contraception contraindicated	Spironolactone 100-150 mg daily + topical retinoid + reliable non-hormonal contraception	Increase spironolactone to 200 mg; consider isotretinoin if no response
Moderate acne with insulin resistance	Combined oral contraceptive + spironolactone + metformin + lifestyle modification	Optimize metformin dose; consider dermatology referral for isotretinoin

Algorithm C: Severe Hormonal Acne

Clinical Scenario	First-Line Approach	Additional Considerations
Severe nodulocystic acne, high scarring risk	Combined oral contraceptive + spironolactone 150-200 mg + early isotretinoin referral	Hormonal therapy continues during and after isotretinoin to prevent relapse
Severe acne, significant psychological distress	Expedited dermatology referral for isotretinoin; concurrent hormonal therapy; mental health support	Close monitoring for depression; do not delay treatment due to psychological symptoms
Severe acne with marked hyperandrogenism	Complete endocrine workup first; combined oral contraceptive + spironolactone 200 mg; treat underlying cause	If tumor excluded and PCOS confirmed, aggressive anti-androgen therapy warranted
Severe acne relapsing after isotretinoin	Combined oral contraceptive + spironolactone 150-200 mg (long-term maintenance)	Relapse suggests hormonal driver; may need repeat isotretinoin course with hormonal maintenance

Treatment Selection Based on Patient Factors

Patient Factor	Preferred Treatment	Avoid or Use Caution
Desires contraception	Combined oral contraceptive (drospirenone or norgestimate-containing)	Progestin-only methods (may worsen acne)
Contraception contraindicated	Spironolactone with reliable non-hormonal contraception	Combined oral contraceptives; ensure pregnancy prevention
Planning pregnancy soon	Topical therapies only; optimize metabolic health	Spironolactone (teratogenic); isotretinoin (teratogenic)
Currently pregnant	Topical erythromycin, azelaic acid, benzoyl peroxide	Retinoids, spironolactone, oral antibiotics (tetracyclines)
Breastfeeding	Topical therapies; erythromycin if oral antibiotic needed	Tetracyclines; spironolactone (limited data)
History of thromboembolism	Spironolactone monotherapy; topical therapies	Combined oral contraceptives (contraindicated)
Renal impairment	Combined oral contraceptive; topical therapies	Spironolactone (hyperkalemia risk); adjust metformin dose
History of depression	Combined oral contraceptive + spironolactone; close monitoring	Monitor mood on any hormonal therapy; isotretinoin requires careful assessment
Perimenopausal	Low-dose combined oral contraceptive or spironolactone; consider hormone therapy	Assess cardiovascular risk before combined oral contraceptive

“What Do I Do If…” Decision Reference

Clinical Situation	Immediate Action	Next Step
Patient on combined oral contraceptive with breakthrough bleeding and acne	Continue current pill for 3 cycles; add topical therapy	If persists, switch to pill with higher estrogen or different progestin
Acne worsens in first 2 months of spironolactone	Reassure patient — initial worsening can occur; continue treatment	Assess at 3 months; consider adding topical therapy or increasing dose
Patient develops breast tenderness on spironolactone	Reduce dose; add combined oral contraceptive if not already on one	Usually resolves with time; consider switching formulation
Patient has elevated potassium on spironolactone	Hold spironolactone; recheck potassium in 1 week	Restart at lower dose if normalizes; ensure no interacting medications
Acne flares before each period despite treatment	Switch to continuous combined oral contraceptive (skip placebo week)	Consider increasing spironolactone dose; perimenstrual topical boost
Patient wants to stop combined oral contraceptive	Counsel about likely acne recurrence; optimize spironolactone dose before stopping	Continue spironolactone with non-hormonal contraception; monitor closely
Acne recurs after isotretinoin course	Start combined oral contraceptive + spironolactone for maintenance	If severe recurrence, may need second isotretinoin course with hormonal maintenance
Patient has both acne and hirsutism	Combined oral contraceptive + spironolactone 100-200 mg (higher end of dosing)	Hirsutism takes 6-12 months to improve; combine with hair removal methods
Teenager with hormonal acne pattern	Consider combined oral contraceptive if appropriate; topical therapies first-line	Spironolactone can be used in post-menarchal teenagers off-label
Patient declines hormonal therapy	Optimize topical regimen; discuss lifestyle modifications (diet, stress)	Consider isotretinoin referral for moderate-severe cases; respect patient autonomy

Monitoring and Follow-up Schedule

Treatment	Initial Follow-up	Monitoring Parameters	Long-term Follow-up
Combined Oral Contraceptive	3 months	Blood pressure; side effects; acne response	Every 6-12 months; annual blood pressure
Spironolactone	4-6 weeks (potassium check); 3 months (efficacy)	Potassium, creatinine at baseline and 4-6 weeks; side effects	Annual potassium if stable; earlier if dose change or new medications
Metformin	3 months	GI tolerability; glucose if diabetic; B12 annually	Every 6-12 months; annual B12 and renal function
Topical Retinoids	6-8 weeks	Irritation, tolerability; initial purging is expected	Every 3-6 months until stable

Troubleshooting Refractory Hormonal Acne

Ask These Questions When Treatment Fails

Was treatment duration adequate? Hormonal therapies require 3-6 months for full effect
Is patient adherence good? Daily medication compliance; proper topical application technique
Is the dose optimized? Spironolactone may need titration to 150-200 mg daily
Are there confounding medications? Review all medications and supplements (biotin, androgens, steroids)
Is the diagnosis correct? Reconsider acne mimickers; repeat examination
Has the underlying cause been addressed? Is insulin resistance adequately managed? Any new endocrine diagnosis?
Are there multiple overlapping causes? Hormonal plus comedogenic products plus stress
Is isotretinoin indicated? Severe or scarring acne warrants dermatology referral

8. Clinical Pearls and Pitfalls

Practical wisdom — learn from successes and avoid common mistakes

Must-Know Clinical Pearls

The U-zone is the key: Acne concentrated along the jawline, chin, and neck strongly suggests hormonal etiology, even when laboratory values are normal. This distribution reflects the high density of androgen receptors in the lower face.

Normal androgens do not exclude hormonal acne: Up to 50% of women with hormonal acne have normal serum androgen levels. End-organ hypersensitivity (increased 5-alpha reductase activity or androgen receptor sensitivity) explains this phenomenon, and these patients still respond well to anti-androgen therapy.

Combination therapy is more effective: Combined oral contraceptive plus spironolactone works better than either alone. The combined oral contraceptive suppresses ovarian androgens and raises sex hormone-binding globulin, while spironolactone blocks peripheral androgen action.

Patience is essential: Hormonal therapies take 3-6 months for full effect. Set expectations early: improvement begins around 6-8 weeks, but optimal results require 6 months of consistent treatment.

Spironolactone is safe in healthy young women: Routine potassium monitoring is not required in healthy women under 45 with normal renal function taking spironolactone for acne. A baseline potassium and single follow-up at 4-6 weeks is sufficient.

Post-pill acne often reveals underlying PCOS: Women who develop acne after stopping combined oral contraceptives should be evaluated for PCOS. The pill was masking the underlying hyperandrogenism.

Hormonal therapy prevents isotretinoin relapse: Women with hormonal acne who complete isotretinoin should start or continue hormonal therapy (combined oral contraceptive and/or spironolactone) to prevent the high relapse rate seen in this population.

Ask about biotin: High-dose biotin supplements (commonly taken for hair and nails) are a frequently overlooked cause of acne. Many patients do not consider supplements as “medications” unless specifically asked.

Critical Pitfalls to Avoid

Dismissing acne as “cosmetic”: Acne causes significant psychological distress, depression, and anxiety. The severity of psychological impact often does not correlate with clinical severity. Take all patients’ concerns seriously.

Using oral antibiotics long-term for hormonal acne: Prolonged antibiotic use promotes resistance, disrupts the microbiome, and does not address the hormonal driver. Antibiotics should be short-term bridges while hormonal therapy takes effect, not maintenance therapy.

Prescribing androgenic progestins: Levonorgestrel, norgestrel, and norethindrone have androgenic activity and can worsen acne. Choose pills with anti-androgenic progestins (drospirenone, norgestimate, desogestrel) or use progestin-free IUD plus spironolactone.

Stopping spironolactone too soon: Some patients experience initial worsening or no improvement in the first 2-3 months. Premature discontinuation misses the opportunity for response. Give at least 3-6 months, and consider dose escalation before declaring failure.

Missing the tumor: Rapid onset of severe acne with virilization (voice deepening, clitoromegaly) should trigger urgent workup for androgen-secreting tumor. Do not assume PCOS without excluding this possibility. Total testosterone greater than 200 ng/dL or DHEAS greater than 700 mcg/dL warrants immediate imaging.

Forgetting to counsel on teratogenicity: Spironolactone causes feminization of male fetuses. Ensure reliable contraception in all women of reproductive potential taking spironolactone. Document counseling.

Overlooking drug-induced causes: Always take a complete medication and supplement history. Biotin, whey protein, anabolic steroids, systemic corticosteroids, and androgenic progestins are common culprits often missed.

Delaying treatment in severe or scarring acne: Every week of delay with active nodular acne increases permanent scarring risk. Initiate aggressive treatment early; refer promptly for isotretinoin when indicated.

Key Takeaways

Hormonal acne is characterized by U-zone distribution (jawline, chin, neck), inflammatory lesions, cyclical flares, and persistence or onset in adulthood
PCOS is the most common underlying cause, but up to 50% of women with hormonal acne have normal serum androgen levels due to end-organ hypersensitivity
The four pillars of acne pathogenesis are sebum overproduction, follicular hyperkeratinization, Cutibacterium acnes colonization, and inflammation — androgens drive the first two
Laboratory evaluation is indicated for hormonal pattern acne, treatment-resistant acne, clinical hyperandrogenism, or menstrual irregularity
First-line testing includes total or free testosterone, DHEAS, and prolactin; add pelvic ultrasound if PCOS is suspected
Combined oral contraceptives with anti-androgenic progestins (drospirenone, norgestimate) plus spironolactone is the most effective regimen for hormonal acne
Spironolactone doses of 100-200 mg daily are typically needed; the drug is safe in healthy young women without routine extensive monitoring
Red flags for tumor include rapid virilization, testosterone greater than 200 ng/dL, DHEAS greater than 700 mcg/dL, or new acne in postmenopausal women
Hormonal therapy should be continued as maintenance after isotretinoin to prevent the high relapse rate in hormonal acne
Always assess the psychological impact of acne and address it as part of comprehensive management

Quick Reference Algorithm

Systematic Approach to Hormonal Acne:

Recognize the pattern: U-zone distribution, inflammatory predominance, cyclical flares, adult onset or persistence
Exclude red flags: Rapid virilization, Cushingoid features, markedly elevated androgens warrant urgent evaluation
Take a complete history: Use the “HORMONAL” mnemonic; include medications, supplements, menstrual history
Perform targeted examination: Assess acne severity and distribution, signs of hyperandrogenism (hirsutism, alopecia, acanthosis nigricans)
Investigate when indicated: First-line tests include testosterone, DHEAS, prolactin; add pelvic ultrasound for suspected PCOS
Initiate hormonal therapy: Combined oral contraceptive with anti-androgenic progestin plus spironolactone for most patients
Set realistic expectations: Improvement begins at 6-8 weeks; optimal response at 3-6 months
Monitor and adjust: Follow-up at 3 months; titrate spironolactone if needed; refer for isotretinoin if severe or refractory
Address psychological impact: Screen for depression and anxiety; expedite treatment for significant distress
Plan long-term maintenance: Hormonal acne typically requires ongoing therapy; plan for pregnancy when relevant

Prescribing Quick Reference

Medication	Starting Dose	Target Dose	Key Counseling Points
Spironolactone	50-100 mg daily	100-200 mg daily	Take with food; expect breast tenderness; strict contraception required; avoid potassium supplements
Combined oral contraceptive (drospirenone)	1 tablet daily	Continuous use for cycle-related flares	Take at same time daily; 3-6 months for acne improvement; report leg pain or shortness of breath
Topical tretinoin	0.025% cream every other night	0.05-0.1% nightly as tolerated	Apply pea-sized amount; expect initial irritation and purging; strict sun protection; not in pregnancy
Metformin (for PCOS with insulin resistance)	500 mg daily with food	1500-2000 mg daily in divided doses	Increase slowly to minimize gastrointestinal side effects; take with meals